Skip to content

The Reducing Risk Study

Reducing Risk: A Comprehensive mHealth Sleep Health Intervention for Adolescents at Risk for Depression and Anxiety Disorders

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03665337
Enrollment
59
Registered
2018-09-11
Start date
2020-09-01
Completion date
2024-10-24
Last updated
2026-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delayed Sleep Phase, Insomnia

Brief summary

The present study will test an innovative mobile health adaptation of a behavioral intervention that improves sleep and mental health concerns among adolescents.

Interventions

BEHAVIORALmTranS-C

MOBILE HEALTH

BEHAVIORALControl

MOBILE HEALTH

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Participants are asked to refrain from mentioning any information about the treatment they receive when interacting with the investigator or outcomes assessors

Eligibility

Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
No

Exclusion criteria

* any current psychiatric illness * currently use of medications or herbs with known effects on sleep * hospitalization for substance use or suicide within the past 12 months * known sleep apnea * unstable major medical conditions * current psychotherapy for depression, anxiety or sleep health deficits

Design outcomes

Primary

MeasureTime frameDescription
Change in Pittsburgh Sleep Quality Index (PSQI)baseline to end of treatment (anticipated average exposure 2 months), months 3 and 8Validated questionnaire; total score range between 0 and 21, with higher numbers representing worse sleep quality

Secondary

MeasureTime frameDescription
Change in the PHQ-9 (The 9 Item Patient Health Questionnaire For Depression)baseline to end of treatment (anticipated average exposure 2 months), months 3 and 8A validated questionnaire measuring depressive symptom severity. The total score ranges between 0 and 19. Scores are rated as minimal (0-4), mild (5-9), moderate (10-14), and severe (15-19).
Change in the SCARED (Screen for Child Anxiety Related Disorders) total scorebaseline, and at months 1, 2, 3 and 8A validated 41-item questionnaire assessing self-report of anxiety in children and adolescents. Individual items are rated 'Not True or Hardly Ever True' (Score 0), 'Somewhat True or Sometimes True' (Score 1), or 'Very True or Often True' (Score 2). Individual response scores are then summed and for a total score. Total scores range from 0 to 82.
Change in cortisol reactivity and recovery in response to a stress exposurebaseline and at month 3A validated biological measure of stress reactivity and recovery in response to a stress exposure. Changes in cortisol production at 15, 30 and 45 minutes following a stressor will be evaluated.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORLauren Asarnow, PhD

University of California, San Francisco

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 25, 2026